Российское сообщество больных Гепатитом С
 

Chapter 3. TREATMENT (Conventional Medicine)

Table of Contents
3.1.0 INTERFERONS
3.1.1 Interferon Monotherapy
3.1.1a Interferon Alpha 2B, Recombinant (Intron A)
3.1.1b When Is Interferon Treatment Not Indicated?
3.1.1c Interferon “Breakthrough” and “Non-Response”
3.1.1d Consensus Interferon (Infergen)
3.1.1e Natural Source Interferon Alpha-N3 – Human Leukocyte-Derived (Alferon)
3.1.1f Beta Interferon, Recombinant (Betaseron, Avonex and Rebif)
3.1.1g Roferon INTERFERON ALPHA 2A, RECOMBINANT
3.1.1h Lymphoblastoid IFN
3.1.1i Mochida Interferon (Alpha IFN-alpha Mochida500)
3.1.1j Multiferon
3.1.1k Veldona Oral Alpha-IFN
3.1.1l Omega IFN (Biomed 510)
3.1.1m Albuferon
3.1.2 Pegylated Interferon
3.1.2a Pegylated Intron A (Peg-Intron A)
3.1.2b Peginterferon Alpha-2a (Pegasys)
3.1.3 Interferon Combinations
3.1.3a Interferon and Ribavirin Combined (Rebetron)
3.1.3b Pegylated IFN and Ribavirin
3.1.3c Interferon and Iron Reduction Therapy
3.1.3d Interferon and Thymosin
3.1.3e Interferon and GM-CSF
3.1.3f Interferon and NAC
3.1.3g Interferon and Amantadine
3.1.3h Interferon and Ofloxacin
3.1.3i Interferon and Histamine Dihydrochloride (Ceplene)
3.1.3j IFN and Ketoprofen
3.1.3k IFN and Ursodeoxycholic Acid (Actigall)
3.1.3l IFN and VX-497
3.1.3m IFN and Colchicine
3.1.3n Triple Therapy
3.1.4 Different Dosage
3.1.4a Mega Dosing
3.1.4b Maintenance Dosing
3.1.4c Induction dosing
3.1.4d Longer Treatment
3.2.0 INTERLEUKINS
3.2.1 Interleukin-10
3.2.2 Interleukin-12
3.3.0 HCV PROTEIN-BASED THERAPY (or GENE THERAPY or RNA INHIBITORS)
3.3.1 Protease Inhibitors
3.3.2 Polymerase Inhibitors
3.3.3 Helicase Inhibitors
3.3.4 Reverse Transcriptase Inhibitors
3.3.5 VP-50406
3.3.6 Interferon Alpha Gene Therapy
3.3.7 Ribozyme Therapy
3.3.8 IRES Inhibitors
3.3.9 Antisense Based Therapies
3.4.0 VACCINES
3.4.1 HCV Antibody
3.4.2 InnoVac-C
3.4.3 HepeX-C (formerly XTL-002)
3.4.4 Epimmune Vaccine
3.4.5 Vical technology
3.4.6 ChimeriVax Vaccine
3.4.7 Chiron Vaccine
3.4.8 Iscoprep 703 (ISCOM)
3.4.9 Therapore
3.4.10 Antigen-specific cellular therapy
3.5.0 OTHER THERAPIES
3.5.1 Nucleoside Analogs
3.5.2 ACH-126447 (Helioxanthin)
3.5.3 Ampligen
3.5.4 EHC18 (Enzo Immune Regulator)
3.5.5 Geron Telomerase Activation
3.5.6 HE2000
3.5.7 Hypericin (Vimrx, Hifritzen)
3.5.8 Immtech Mono and Dication Compounds
3.5.9 IP501
3.5.10 Macrokine (WF10)
3.5.11 S-28463 (R-848; VML-600)
3.5.12 NCX-1000
3.6.0 TRANSPLANT
3.7.0 OTHERS

(A big thank you to Joan King of HepCBC for updating this section)

3.1.0 INTERFERONS

A number of new therapies for hepatitis C are emerging in clinical practice. Pegylated interferon plus ribavirin has proved much more effective than interferon alone, or the IFN + ribavirin combo, and at this time is considered to be the preferred treatment. Trials are being done with combinations of interferon and other substances, with re-treatment, with different types and brands of interferon, with longer-term therapy, long-term maintenance therapy, high-dose induction therapy, and with the more effective pegylated interferons, also combined with such substances as amantadine and thymosin. Promising research is being done on therapeutic vaccines and such things as polymerase inhibitors, protease inhibitors, helicase inhibitors, glucosidase inhibitors, IRES inhibitors, antisense oligonucleotides, and ribozymes, polyclonal antibodies, cytokine inducers, as well as treatments to reverse fibrosis, and to create new liver cells. It is possible that treatment in the future will be tailor-made to fit the patient in terms of genotype and viral load.



Реклама:



Реклама:

Яндекс цитирования

Сайт управляется системой uCoz